Ronnie Andrews: Thanks everyone for joining today. Mitch and I were out traveling in the summer and the fall meeting with investors and different groups at different meetings. It became apparent that many of you had questions about a lot of the announcements we're making, how...

SAN FRANCISCO - February 15, 2022 - Cofactor Genomics today announced publication in the latest issue of Nature Scientific Reports of a study showing that the company’s multianalyte biomarkers based on T cell subtype profiling (TCSP) predicted patient response to anti-PD-1 the...

Ronnie Andrews, Chief Executive Officer Welcome everyone, to our conference call to discuss our third quarter 2021 financial results and operating highlights. Joining me on today's call are Mitch Levine, Chief Financial Officer; Gisela Paulsen, our new Chief Operating Officer...

Since launching DetermaRx™ , we have identified over 500 patients as having a “high risk” of recurrence of their lung cancer. Without action, nearly half of these patients are likely to lose their life within five years. Instead, the patients classified as high-risk are indic...

On today’s call, I’ll review the significant progress we continue to make across our initial four growth engines which together, aim to provide a single solution to answer key, outstanding questions for patients and physicians regarding the treatment of solid tumors throughout...

The KOL Webinar featured a presentation by Key Opinion Leaders (KOLs) Priyanka Sharma, MD (University of Kansas Medical Center) and Giampaolo Bianchini, MD (San Raffaele Hospital, Milano, Italy). Dr. Sharma discussed the unmet need for identifying patients with triple-negati...

Ronald Andrews, CEO, Oncocyte Over the past year, we've made great strides in advancing our mission to create a one-stop lab of comprehensive molecular diagnostic offerings that answer critical unanswered questions for physicians and patients for the management of solid tumors...

The event will feature a presentation by Key Opinion Leaders (KOLs) David Gandara, MD (UC Davis Comprehensive Cancer Center) and Mamta Parikh, MD, MS (UC Davis Comprehensive Cancer Center), who will present an overview of the use and limitations of currently clinically availa...

SAN FRANCISCO, Calif. – April 13, 2021 – Cofactor Genomics, the company bridging the precision medicine gap, today announced commencement of the first multicenter clinical trial of its OncoPrismTM diagnostic assay, using the company’s patented approach to generating multidimen...

Oncocyte Corp. (OCX) management is focused on two things, expansion and execution. With several upcoming events and milestones on the horizon, building significant shareholder value is the primary goal. These milestones include driving awareness and sales uptake for DetermaRx™...